Portman Square Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Portman Square Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.9M	Buy	46,200 +8,300	+22%	+$2.5M	0.66%	44
2026 Q1	$12.5M	Buy	37,900 +8,900	+31%	+$3.03M	0.48%	57
2025 Q4	$11.5M	Buy	29,000 +4,000	+16%	+$1.77M	0.51%	48
2025 Q3	$11.4M	Sell	25,000 -11,000	-31%	-$4.48M	0.5%	44
2025 Q2	$11.7M	Hold	36,000	–	–	0.34%	65
2025 Q1	$9.72M	Sell	36,000 -5,600	-13%	-$1.44M	0.26%	107
2024 Q4	$9.79M	Buy	41,600 +10,000	+32%	+$2.63M	0.35%	68
2024 Q3	$8.69M	Sell	31,600 -24,700	-44%	-$6.43M	0.32%	99
2024 Q2	$13.7M	Hold	56,300	–	–	0.47%	62
2024 Q1	$8.41M	Buy	56,300 +5,300	+10%	+$884K	0.23%	116
2023 Q4	$9.76M	Hold	51,000	–	–	0.22%	121
2023 Q3	$9.03M	Buy	51,000 +30,000	+143%	+$5.72M	0.22%	119
2023 Q2	$3.99M	Sell	21,000 -33,000	-61%	-$6.54M	0.11%	173
2023 Q1	$10.8M	Buy	54,000 +24,000	+80%	+$5.04M	0.5%	45
2022 Q4	$7.13M	Buy	+30,000	New	+$6.4M	0.53%	50

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Portman Square Capital's ALNY Position: Q2 2026 in Review

Portman Square Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 48% in Q2 2026, buying an estimated $2.44M and bringing the position to 25,016 shares worth $7.53M. The position accounts for 0.36% of the portfolio, ranked #58.

Portman Square Capital first reported a position in ALNY in Q1 2023 and has held it in 13 quarters since. 141 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Portman Square Capital held 25,016 shares of Alnylam Pharmaceuticals worth $7.53M as of Q2 2026.
Portman Square Capital bought 8,092 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.44M.
Alnylam Pharmaceuticals made up 0.36% of Portman Square Capital's portfolio in Q2 2026, its #58 holding.
Portman Square Capital first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
141 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Portman Square Capital's 13F filing for Q2 2026, filed 15 Jul 2026.